Skip to main content

Table 3 Baseline factors associated with disease relapse using Cox proportional hazards regression models

From: Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study

Baseline characteristics Univariate Multivariate
HR (95% CI; p value) HR (95% CI; p value)
Calprotectin (μg/mL) 2.38 (1.79–3.16; < 0.0001) 2.74 (1.71–4.41; < 0.0001)
Power Doppler score, 0–66 1.31 (1.18–1.45; < 0.0001)  
TNFi trough serum levels (μg/mL) 0.47 (0.26–0.88; 0.018) 0.36 (0.10–1.30; 0.120)
DAS-ESR 2.10 (0.72–6.18; 0.175)  
Time-to-remission (months) 1.17 (1.11–1.23; < 0.0001)  
Time-in-remission (months) 0.98 (0.97–1.00; 0.087)  
Female gender 1.25 (0.38–4.15; 0.716)  
Disease duration (months) 1.02 (0.96–1.08; 0.510)  
Diagnosis, RA/PsA 2.39 (0.72–7.93; 0.155) 0.80 (0.10–6.30; 0.832)
Age (years) 0.98 (0.94–1.03; 0.535)  
Monotherapy 0.36 (0.10–1.33; 0.125) 0.51 (0.08–3.35; 0.484)
Steroids 3.12 (1.02–10.1; 0.046) 0.22 (0.04–1.21; 0.082)
  1. Significant values are shown in bold typeface
  2. CI confidence interval, DAS-ESR Disease Activity Score-erythrocyte sedimentation rate, HR hazard ratio, PsA psoriatic arthritis, RA rheumatoid arthritis, TNFi tumor necrosis factor inhibitors